1 Min Read
Feb 26 (Reuters) - Eli Lilly And Co:
* ELI LILLY SAYS NEW DATA SHOW TRULICITY (DULAGLUTIDE) IN COMBINATION WITH SGLT-2 INHIBITOR IMPROVES BLOOD SUGAR CONTROL IN PEOPLE WITH TYPE 2 DIABETES Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.